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Background: Cardiogenic shock is the leading cause of death in patients with acute myocardial infarction. Despite
significant advancements in health technology and research, hospital mortality approaches 50%. The intra-aortic
balloon pump is a mechanical hemodynamic assist device that has been used for over 40 years in the management
of patients with cardiogenic shock. A recent randomized trial suggests that the use of intra-aortic balloon pumps does
not reduce mortality in patients with ischemic cardiogenic shock.
Methods: We plan to search MEDLINE, EMBASE, and the Cochrane Trial Registry for potentially eligible randomized
trials that compare the use of intra-aortic balloon pump with no mechanical device support in patients with
cardiogenic shock. No date, language or journal limitations will be applied. Two reviewers will independently
screen and identify eligible studies using predefined eligibility criteria. Data abstraction will be done independently
and in duplicate. We plan to use RevMan software to generate pooled estimates across included studies, using the
previously published method of DerSimonian and Laird. We will report pooled estimates as risk ratios with 95%
confidence intervals for binary outcomes, and as mean differences with 95% confidence intervals for continuous
outcomes. We will assess the quality of evidence using the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach.
Discussion: The aim of this systematic review and meta-analysis is to summarize the available evidence on the efficacy
of the intra-aortic balloon pump in cardiogenic shock.
Systematic review registration: PROSPERO CRD42014007056.
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Description of the condition
Cardiogenic shock occurs as a consequence of cardiac
pump failure. Pump failure can lead to decreased cardiac
output and a subsequent increase in systemic vascular
resistance, in order to maintain perfusion of vital organs.
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unless otherwise stated.(systolic blood pressure <80 to 90 mmHg or mean arter-
ial pressure 30 mmHg lower than baseline) with severe
reduction in the cardiac index (<1.8 l.min−1.m2 without
support or <2.0 to 2.2 l.min−1.m2 with support) and ad-
equate or elevated ventricular filling pressures. Cardio-
genic shock complicates approximately 5% of myocardial
infarctions. Despite utilization of an early revasculariza-
tion strategy and advancing health care, cardiogenic
shock remains the leading cause of death in this popula-
tion with a hospital mortality rate approaching 40 to
50% [1,2]. Intra-aortic balloon pump (IABP) counterpul-
sation is a commonly used mechanical hemodynamicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has been the subject of ongoing debate. Improved
hemodynamics using an IABP in patients with cardio-
genic shock have been reported anecdotally by care pro-
viders, with registry-based observational studies [3,4]
suggesting potential benefit. However, a recent random-
ized trial showed no effect on 30-day mortality using an
IABP compared with standard of care.Description of the intervention
IABP represents one type of mechanical hemodynamic
support device, and it has emerged as the single most
widely used circulatory assist device worldwide. The ef-
fect of IABP on coronary blood flow is variable. Some
studies found little or no change in coronary blood flow
[5-7] while others noted a significant increase [8,9].How the intervention might work
When the balloon inflates during diastole, blood is dis-
placed into the proximal aorta. Subsequently, rapid bal-
loon deflation during systole reduces aortic volume
(afterload) by creating a vacuum-like effect. These effects
are variable, and may depend on the volume of the bal-
loon, position in the aorta, heart rate, rhythm, and other
factors [8].
The hemodynamic effects of IABP may include a re-
duction in systolic blood pressure and an increase in
aortic diastolic pressure, resulting in higher coronary
blood flow. The net result is a reduced heart rate and
pulmonary capillary wedge pressure and an increased
cardiac output [8].Why this review is important
Since the publication of the most recent systematic re-
view on this topic [10], a large randomized controlled
trial (RCT) has been published [2]. Although the results
of this RCT do not support the use of IABP in patients
with cardiogenic shock, an updated review is needed, to
summarize and assess the quality of available evidence.Objectives
We plan to conduct a systematic review and meta-
analysis of RCTs to investigate the potential benefits and
risks of using IABP in patients with cardiogenic shock
secondary to acute myocardial infarction.Methods
Types of study
We will include parallel group RCTs with no methodo-
logical quality restriction. Quasirandomized (pseudoran-
domized) trials and crossover studies will be excluded.Types of participant
The population of interest includes adult patients
(age ≥18 years old) with cardiogenic shock (excluding
mechanical cardiac complications) complicating acute
myocardial infarction. Studies should be conducted in
either intensive care unit or coronary care unit settings.Types of intervention
The intervention of interest is IABP counterpulsation.
Studies that used other cardiac support devices, such as
a left ventricular assist device or an extracorporeal mem-
brane oxygenator are not eligible. The control group
should be standard medical therapy only; studies compar-
ing IABP with other support devices will be excluded.Types of outcome measure
Primary outcomes
Our primary outcome measure is all-cause mortality at
hospital discharge. If this is not available, the longest re-
ported mortality will be used (for example, if both 30- and
90-day mortality are reported, we will use data on 90-day
mortality in the analysis of the primary outcome).Secondary outcomes
Secondary outcome measures include:
1. Length of stay (days) in intensive or coronary care
unit;
2. Stroke (ischemic or hemorrhagic);
3. Re-infarction;
4. Limb ischemia;
5. Clinically significant bleeding (defined as any
bleeding that requires transfusion of more than two
units of blood, or that is associated with
hemodynamic instability not explained by other
conditions).Search methods for identification of studies
Electronic searches
We will search the electronic databases MEDLINE and
EMBASE and the Cochrane Trial Registry for eligible ar-
ticles from inception to November 2013. We plan to use
search terms that include IABP, cardiogenic shock, and a
sensitive RCT filter for each database (Additional file 1).Searching other resources
Two reviewers will independently search reference lists
of review articles and systematic reviews for eligible arti-
cles. Abstracts in conferences and proceedings will be
searched using a database provided through McMaster
University’s electronic library, PapersFirst [11].
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After identification of potentially relevant articles, two
reviewers (SA) and (AA) will independently screen all ci-
tations and references using specific eligibility criteria.
The kappa statistic will be used to measure agreement
between reviewers [12]. Disagreement will be resolved
by discussion and consensus, with the help of a third re-
viewer (WA) when required.
Selection of studies
We will apply the following eligibility criteria:
1. Population: adult (18 years or older) patients with
cardiogenic shock secondary to acute myocardial
infarction;
2. Intervention: IABP along with standard medical
therapy compared with standard medical therapy
alone;
3. Outcomes (at least one): all-cause mortality, ICU
length of stay, stroke, limb ischemia, or clinically
significant bleeding;
4. Design: RCT. Quasi-randomized (pseudo-randomized)
and crossover studies will be excluded.
Data extraction and management
Data extraction will be done independently and in dupli-
cate using predesigned data abstraction forms (Additional
file 2). Abstracted data will contain: study title, authors’ in-
formation, relevant demographic data, the type of inter-
vention and control, definitions and numerical data for
outcomes of interest and data on methodologic quality for
each included study. Disagreement will be resolved by dis-
cussion and consensus with help of a third reviewer (WA)
when required.
Assessment of risk of bias in included studies
In duplicate and independently, two reviewers will assess
the methodological quality of individual trials utilizing
the Cochrane tool for assessing risk of bias [13].
For each included study, we will provide a description,
comment, and judgment of ‘Yes’, ‘Unclear’, or ‘No’ for
each of the following items:
Adequate sequence generation (selection bias)
Sequence generation will be considered adequate if it
was generated by computer or using published tables of
random numbers. Coin-tossing, dice-throwing, and deal-
ing shuffled cards will also be considered adequate
methods of sequence generation.
Allocation sequence concealment (selection bias)
The concealment of the allocation sequence will be con-
sidered adequate when specific methods have been im-
plemented to undoubtedly protect knowledge of theallocation before and until the participant was assigned
to one of the trial arms.
Blinding of participants and researchers (performance bias)
Owing to the nature of the intervention, it will be im-
possible to blind patients, physicians, and caregivers.
Risk of bias due to blinding will be assessed for each of
the outcomes within each included study. For objective
outcomes, such as mortality, stroke, and limb ischemia,
the effect of lack of blinding is unlikely to bias the
results.
Blinding of outcome assessment (detection bias)
Blinding will be considered adequate if outcome asses-
sors and adjudicators are all blinded. Risk of bias due to
blinding will be assessed for each of the outcomes within
each included study.
Incomplete outcome data assessed (attrition bias)
We will assess studies for attrition bias whenever data is
available on the number of patients at different stages of
the study.
Free of selective reporting (reporting bias)
Selective outcome reporting will be assessed whenever
the protocol of the study is available (as a separate publi-
cation of the protocol, as a registered protocol in elec-
tronic clinical trials registers, or as method section in a
preliminary or abstract publication of the same study).
Free other bias
Other sources of potential bias will be considered (for
example, stopping trials early for benefit, baseline imbal-
ance, or blocked randomization in unblended trials) The
judgment for each category will be made, taking into
consideration the effect of this domain across outcomes
for a single trial. The following categories will be consid-
ered: low risk of bias: when bias is not present or, if
present, is unlikely to alter the results seriously; unclear
risk of bias: when the risk of bias raises some doubt
about the results or the information reported does not
allow for proper assessment; and high risk of bias: when
bias may seriously alter the results and interpretation.
The overall risk of bias for an individual study will be
categorized as ‘low’ (if the risk of bias is low in all do-
mains), ‘unclear’ (if the risk of bias is unclear in at least
one domain, with no high risk of bias domains), or ‘high’
(if the risk of bias is high in at least one domain). Agree-
ment will be reached by consensus or by consulting a
third reviewer (AFR).
Measures of treatment effect
We will use RevMan 5.2 to conduct the meta-analyses.
We plan to report pooled outcomes as risk ratios with
Altayyar et al. Systematic Reviews 2014, 3:24 Page 4 of 5
http://www.systematicreviewsjournal.com/content/3/1/2495% confidence intervals (CIs) for binary outcomes, and
as mean differences with 95% CIs for continuous out-
comes. Applying inverse variance weighting and the
methods of DerSimonian and Laird [14], a random-
effects model will be used, except if we include three
or RCTs or fewer, or if a dominant trial is included
(weight >50%). In the case of low event rates (less than 1%),
the Peto odds ratio will be used to pool binary outcomes
[15]. The number needed to treat will be derived from
the pooled risk ratios, using the approach recommended
by the Cochrane collaboration. When data are not suitable
for pooling we will describe them qualitatively.
Dealing with missing data
We will contact the authors of the primary studies for
additional information on missing data. If this approach
is not successful, we will analyze only the available data
and discuss the potential impact of missing data on the
findings of the review in the discussion section.
Assessment of heterogeneity
We will assess for heterogeneity between studies using
the Mantel-Haenszel χ2 statistic (P < 0.01 indicating sub-
stantial heterogeneity) and the I2 statistic [16]. We con-
sider I2 > 50% to indicated a significant heterogeneity
worthy of investigation. In the case of a significant statis-
tic (for example, I2 > 80%) or clinical heterogeneity that
is not explained by subgroup or sensitivity analysis we
will not conduct a meta-analysis, and will instead de-
scribe the data qualitatively.
Assessment of reporting biases
We will assess publication bias visually using a funnel
plot generated using RevMan 5.1 software, and statisti-
cally using the Egger test [17]. If fewer than ten RCTs
are included, we cannot reliably assess for publication
bias.
Subgroup analysis and investigation of heterogeneity
To explore significant heterogeneity, when possible we
will conduct the following subgroup analyses:
1. Risk of bias: high versus low risk of bias,
hypothesizing that high risk of bias studies will have
a larger effect size;
2. Age: younger than 50 years old versus 50 years and
older, hypothesizing that the younger age group will
have a larger treatment effect;
3. Use of fibrinolysis versus percutaneous coronary
intervention (PCI), hypothesizing that the use of PCI
will attenuate the effect of intervention;
4. Infarct-related artery or territory (anterior versus others);
5. History of pre-existing myocardial infarction versus
no history of myocardial infarction;6. Timing of IABP insertion: IABP insertion before PCI
versus after PCI.
We anticipate that all subgroup analyses will be chal-
lenging, owing to the lack of data and the anticipated
small number of included studies.
Sensitivity analysis
For the primary outcome (mortality), when possible we
will conduct the following sensitivity analyses:
1. Random-effects, or fixed effect model;
2. Excluding studies published as abstracts;
3. Excluding high risk of bias studies.
We will describe the effects (if any) of sensitivity ana-
lyses on the overall results in the results section.
Assessing the quality of evidence
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach
to assess the quality of evidence for each outcome [18]
and to assess the overall quality of evidence. We will
judge the quality of evidence based on five criteria: risk
of bias, inconsistency, imprecision, indirectness, and
publication bias. Based on these criteria, the quality of
evidence judgment could range from very low to high.
Discussion
This systematic review will identify and synthesize evi-
dence examining the potential benefits and harms of
using IABP in patients with cardiogenic shock. Given
the emergence of new evidence, and the lack of an up-
dated systematic review, this review will help in sum-
marizing the available evidence, both quantitatively and
qualitatively.
Additional files
Additional file 1: Search strategy. Search terms for MEDLINE and
EMBASE databases.
Additional file 2: Data abstraction form. Contains data abstraction
tables, and risk of bias assessment table.
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